Concord Medical Services Holdings Ltd
CCMDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Mesenchymal stromal cells (MSC) for infusion | Phase 2 | Crohn Disease | - | - |
Frequently asked questions
What is in Concord Medical Services Holdings Ltd's drug pipeline?→
CatalystAlert tracks 1 drug candidate in Concord Medical Services Holdings Ltd's (CCM) pipeline across Phase 2. Its lead program is Mesenchymal stromal cells (MSC) for infusion (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Concord Medical Services Holdings Ltd's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Concord Medical Services Holdings Ltd (CCM) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CCM biotech catalysts?→
Add CCM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Concord Medical Services Holdings Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.